Turkish Journal of Surgery

Turkish Journal of Surgery

ISSN: 2564-6850
e-ISSN: 2564-7032

 

Süleyman Kargın1, Murat Çakır2, Ebubekir Gündeş2, Yusuf Yavuz2, Hacı Hasan Esen3, M. Sinan İyisoy4, Naile Kökbudak3, Tevfik Küçükkartallar2

1Clinic of General Surgery, Konya Training and Research Hospital, Konya, Turkey
2Department of General Surgery, Necmettin Erbakan University Faculty of Medicine, Konya, Turkey
3Department of Medical Pathology, Necmettin Erbakan University Faculty of Medicine, Konya, Turkey
4Department of Medical Statistics, Necmettin Erbakan University Faculty of Medicine, Konya, Turkey

Keywords: Gastrointestinal stromal tumor, neutrophil lymphocyte ratio, prognosis

Abstract

Objective: Gastrointestinal stromal tumors are believed to play a role in immunosuppression with their local effect. In some cancers with associated inflammation, an increased pretreatment neutrophil lymphocyte ratio is considered as an indicator of poor prognosis. The aim of our study was to assess the relationship of increased blood neutrophil lymphocyte ratio with disease prognosis in patients with gastrointestinal stromal tumors.
Material and Methods: The data of 78 patients who underwent surgery with the diagnosis of primary gastrointestinal stromal tumor in our clinic were evaluated retrospectively. The preoperative neutrophil lymphocyte ratio in the peripheral blood was determined. The neutrophil lymphocyte ratio and its relationship with tumor risk and prognosis were compared. The data were evaluated by Pearson’s correlation analysis and the Welch ANOVA test.
Results: The preoperative neutrophil lymphocyte ratio was significantly increased in the high-risk groups (p<0.05). An increased preoperative neutrophil lymphocyte ratio was associated with shorter survival (r=-0.32, p=0.009). In addition, an increase in the neutrophil lymphocyte ratio was associated with an increase in the mitotic activity of the tumor (r=-0.364, p=0.025).
Conclusion: The preoperative neutrophil lymphocyte ratio in gastrointestinal stromal tumors can be used as an indicator of high-risk tumors and poor prognosis.

Ethics Committee Approval

Ethics committee approval was received for this study from the ethics committee of Necmettin Erbakan University Clinical Research (2012-69).

Peer Review

Externally peer-reviewed.

Author Contributions

Concept - S.K., T.K.; Design - S.K.; Supervision - M.Ç., Y.Y.; Funding - Y.Y., E.G.; Materials - S.K.; Data Collection and/or Processing - S.K., Y.Y.; Analysis and/or Interpretation - H.H.E., N.K.; Literature Review - M.S.İ.; Writer - S.K.; Critical Review - M.S.İ.

Conflict of Interest

No conflict of interest was declared by the authors.

Financial Disclosure

The authors declared that this study has received no financial support.